Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06067841 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

A Phase 1 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Bristol-Myers Squibb.

Compiled by PlainTrial · August 8, 2026

Recruiting
Registry status: Phase 1
Development phase: 140
Enrollment target: 8
Study locations

NCT06067841: Recruiting Phase 1 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by Bristol-Myers Squibb.

NCT06067841 is a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 140 participants, below the 196-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (29% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06067841, a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer, is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status: Phase 1
Development phase: 140 participants
Enrollment target: 8
Study locations

Study Summary

The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer

Interventions

DRUG BMS-986460

Study Locations (8)

Texas

Local Institution - 0006 - San Antonio
NEXT Oncology - San Antonio

California

Stanford Cancer Center - Palo Alto

Florida

Florida Cancer Specialists Sarasota Drug Development Unit - Sarasota

Massachusetts

Dana-Farber Cancer Institute - Boston

New York

Memorial Sloan Kettering Cancer Center - New York

North Carolina

Duke Cancer Institute - Durham

Washington

Fred Hutchinson Cancer Center - Seattle

Trial Details

Field	Value
Enrollment Target	140 participants
Start Date	2023-10-18
Est. Completion	2031-07-27
Phase	Phase 1

Bristol-Myers Squibb

1,025 total trials

What NCT06067841 shows while recruiting

NCT06067841 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 196-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (29% lower).

The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which BMS-986460 is the first listed.

NCT06067841 lists 8 locations in 7 states (Texas, California, Florida).

Frequently Asked Questions

What is clinical trial NCT06067841 about?

NCT06067841 is a clinical study titled "A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer". The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.

What is the current status of trial NCT06067841?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2023-10-18. Estimated completion is 2031-07-27.

What conditions does trial NCT06067841 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.

What interventions are being tested in trial NCT06067841?

The interventions under investigation include: BMS-986460 (DRUG).

Who is sponsoring clinical trial NCT06067841?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06067841 being conducted?

This trial has 8 study locations across California, Florida, Massachusetts, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06067841's enrollment target sits among peer trials

140 23rd of 69 higher than 46 of 69 other Metastatic Castration-Resistant Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Castration-Resistant Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia

Similar registry start date

NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06067841, the US trial registry maintained by the National Library of Medicine. NCT06067841 (mid enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.